Should I buy Insulet Corporation (PODD) stock or is it too late?

Insulet Corporation · Health Care · price $143

See the full Insulet Corporation (PODD) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Deutsche Bank — 72% of its targets hit on this sector (291 calls tested). It aims for $190 (+33 %), call made on June 24, 2026, maturing on June 24, 2027 (65 d ago).

The 12 reliable analysts $163+13 %

The 8 other firms $209+46 %

How to read it: the 12 reliable firms are not filtered by optimism — 12 aim above the price, 0 below, hence their $163 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Insulet Corporation

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
BTIG	89 %	+48.0 %	9	$235 +64%
Canaccord Genuity	71 %	+26.9 %	14	$179 +25%
JP Morgan	75 %	+24.6 %	8	$152 +6%
Raymond James	54 %	+14.2 %	26	$360 +151%
Citigroup	67 %	+13.3 %	9	$172 +20%
Wells Fargo	40 %	-7.9 %	5	$144 +0%
Jefferies	67 %	+30.0 %	9	—
Piper Sandler	67 %	+22.2 %	9	—

In short — Should you invest in Insulet Corporation? Is it too late, still worth it? Analysts are split (50% buy, median target $179, i.e. +25%), and the most reliable on PODD targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $179, i.e. +25% from the current price ($143).
The most reliable firm on PODD, UBS (100% hit rate, 3 scored calls), targets $150 (call made on August 6, 2026, maturing on August 6, 2027) (+5%) in its most recent call.
5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 20 ratings, 9 are neutral and 1 is a sell.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on PODD

Median target $179 (+25%) · 20 ratings · Hold consensus

Strong Buy00%

Buy1050%

Hold945%

Sell15%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Insulet Corporation now?

We won't decide for you. The facts: 50% of analysts rate it a buy, median target $179 (+25%), and UBS (most reliable on PODD, 100%) targets $150. Weigh that against valuation (P/E ~27). This is not personalized advice.

Is it too late to invest in Insulet Corporation?

Not according to analysts: the median target ($179) is still +25% above the current price ($143) (most reliable on PODD: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Insulet Corporation still worth investing in?

It depends on the gap between the price ($143) and its estimated value: analysts target $179 on median (+25%), with 50% buys (most reliable on PODD: UBS, 100%). Cross-check with their real reliability on PODD and the cautions above. Information, not advice.

What's the main risk in buying PODD?

The consensus is not unanimous: of 20 ratings, 9 are neutral and 1 is a sell.

→ Go deeper: the full Insulet Corporation profile (consensus, analyst reliability, price target, performance).